N. Aucoin

发表

Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial

M. Chamberlain, Philippe Bédard, V. Borges, 2018, JAMA oncology.

Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial.

W. Scheithauer, F. Bonnetain, A. de Gramont, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Forearm vasoreactivity in type 1diabetic subjects.

R. Wood, M. Welsch, J. Allen, 2001, Canadian journal of applied physiology = Revue canadienne de physiologie appliquee.

Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.

W. Shabana, T. Vuong, P. Kavan, 2015, Current oncology.

497OBEVACIZUMAB-ERLOTINIB AS MAINTENANCE THERAPY IN METASTATIC COLORECTAL CANCER. FINAL RESULTS OF THE GERCOR DREAM STUDY.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

D. Tu, S. Gill, S. Welch, 2022, Nature Communications.

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

C. Tournigand, W. Scheithauer, D. Vernerey, 2015, The Lancet. Oncology.

A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada.

H. Kennecke, P. Kavan, J. Maroun, 2019, Current oncology.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.

C. Falkson, R. Burkes, J. Maroun, 2015, Current oncology.

LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

D. Tu, S. Gill, S. Welch, 2020 .

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer

D. Tu, H. Kennecke, P. Kavan, 2020, JAMA oncology.

Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.

F. Saad, S. Berry, S. Sridhar, 2016, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).

D. Tu, H. Kennecke, P. Kavan, 2019, Journal of Clinical Oncology.

Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).

F. Saad, S. Berry, S. Sridhar, 2014 .

Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

D. Tu, S. Gill, S. Welch, 2021 .

Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2015 .

Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.

P. Bedard, V. Borges, S. Welch, 2016 .

Abstract P4-14-20: A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)

P. Bedard, V. Borges, S. Welch, 2016 .

Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer

E. Titmuss, J. Goffin, J. Loree, 2023, JAMA network open.

Quality of life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel.

F. Saad, S. Berry, S. Sridhar, 2013 .

Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2013 .